2seventy bio (NASDAQ:TSVT – Get Free Report)‘s stock had its “sell (e+)” rating reiterated by Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.
2seventy bio Price Performance
Shares of TSVT stock opened at $2.59 on Friday. 2seventy bio has a one year low of $2.35 and a one year high of $6.40. The business’s 50 day simple moving average is $3.02 and its 200 day simple moving average is $4.02. The stock has a market capitalization of $133.62 million, a PE ratio of -1.39 and a beta of 1.74.
Institutional Trading of 2seventy bio
Institutional investors and hedge funds have recently modified their holdings of the business. BBR Partners LLC grew its stake in shares of 2seventy bio by 620.0% in the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after buying an additional 155,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in 2seventy bio by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after purchasing an additional 13,144 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of 2seventy bio in the third quarter worth $64,000. FMR LLC grew its position in 2seventy bio by 22.0% during the third quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares during the period. Finally, State Street Corp raised its holdings in 2seventy bio by 1.5% in the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock worth $4,997,000 after purchasing an additional 15,638 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.
About 2seventy bio
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than 2seventy bio
- Health Care Stocks Explained: Why You Might Want to Invest
- How to Invest in Small Cap Stocks
- Bank Stocks – Best Bank Stocks to Invest In
- These Are the Dividend Stocks Insiders Bought in January
- Growth Stocks: What They Are, Examples and How to Invest
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.
